CLSN Projected Dividend Yield
Com Par 2022 (New)/Celsion Corp ( NASDAQ : CLSN )Celsion is a clinical stage biotechnology company. Co.'s product pipeline includes GEN-1, a DNA-based immunotherapy for the treatment of ovarian cancer. ThermoDox®, Co.'s proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications, which is being managed though Co.'s wholly owned subsidiary, Celsion GmbH. Additionally, Co. has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines and other anti-cancer DNA or RNA therapies. Both are synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. 20 YEAR PERFORMANCE RESULTS |
CLSN Dividend History Detail CLSN Dividend News CLSN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |